ClinicalTrials.gg
CompletedNCT05543369Updated Feb 20, 2025

Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

A Phase 1 interventional study of Elafibranor in Healthy Volunteers, sponsored by Ipsen. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Ipsen · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2023, 3 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is intended to measure the blood levels of Elafibranor and one of its metabolites in Japanese and non-Asian Healthy Participants, to be able to compare how the body absorbs, distributes, and eliminates Elafibranor after Repeat Administration, in order to support inclusion of Japanese patients in the planned clinical studies with elafibranor.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Pharmacokinetics
  • Elafibranor
03

In context

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants should meet one of the following ethnicity criteria:

    1. Japanese:

      • Must have been born in Japan.
      • Both the subject's biological parents and all four biological grandparents must be Japanese, as confirmed by interview.
      • Must not be living outside of Japan for more than 10 years.
      • Lifestyle, including diet, has not changed significantly since leaving Japan
    2. Non-Asian:

      • Must be a descent from North America, South America, Europe or the Middle East (subjects from Asian/Pacific Islander and African American descent are excluded).
      • Both the subject's biological parents and all four biological grandparents must be of non-Asian descent
  • Male or female participants must be 18 to 55 years of age (inclusive) at the time of signing the . A minimum of six evaluable subjects of each sex will have to be completed within each cohort (i.e. at least six female and six male subjects)
  • Has provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
  • Willingness to remain at the clinic for the required duration and willingness to return to the clinic for the follow-up evaluation as specified in the protocol
  • Healthy participants as determined by medical evaluation at the screening visit including medical history, physical examination, laboratory tests, (ECG) and vital signs monitoring
  • Laboratory parameters within the normal range of the laboratory (haematological, blood biochemistry, urinalysis). Individual values out of the normal range can be accepted if judged non- by the investigator.
  • Normal ECG recording on a 12-lead ECG at screening and at admission (Day -1):

    • 120≤PR≤220 ms,
    • QRS\<110 ms,
    • ≤430 ms for male and ≤450 ms for female,
  • No evidence of sinus node automaticity or abnormal conduction, or rhythm disorders of concern, except as considered non-clinically significant by the investigator. Out-of-range values that are not clinically significant (as determined by the investigator) may be repeated twice during screening and admission and the participant may be enrolled if at least one repeated value is within the range noted above.
  • Normal blood pressure (BP) and heart rate (HR) at the screening and at admission after 5 minutes in supine position:

    • 90 mmHg ≤ systolic blood pressure (SBP)≤145 mmHg
    • 50 mmHg ≤ diastolic blood pressure (DBP)≤90 mmHg,
    • 45 bpm≤HR≤90 bpm,
  • For these parameters, out-of-range values that are not clinically significant (as determined by the investigator) may be repeated twice during screening and admission and the participant may be enrolled if at least one repeated value is within the range noted above.
  • Body weight not below 45 kg and (BMI) within the range 18.0 kg/m\^2 and 30.0 kg/m\^2
  • /Barrier Requirements:

    1. Female participants:

      • A female participant is eligible to participate if she is not pregnant or breastfeeding at screening, is willing not to become pregnant during the study and one of the following conditions applies:
      • Is a woman of nonchildbearing potential (WONCBP), or
      • Is a woman of (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, during the study intervention period and for at least one month after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (e.g. noncompliance, recently initiated) in relationship to the first dose of study intervention.
      • A WOCBP must have a negative highly sensitive pregnancy test (serum as required by local regulations) within 24 hours before dosing with study intervention. The investigator is responsible for review of medical history, menstrual history and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
    2. Male participants:

      • Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of study intervention:
      • Refrain from donating sperm PLUS, either:
      • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, or
      • Must agree to use contraception /barrier as detailed below:
      • Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak and there remains a risk to pregnant women and women of childbearing potential

Exclusion criteria

Exclusion Criteria :

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, haematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data
  • Lymphoma, leukaemia or any within the past 5 years except basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years prior to screening
  • Breast cancer within the past 10 years prior to screening
  • Major surgery within 28 days prior to screening
  • History of COVID-19 infection (hospitalization, extracorporeal membrane oxygenation, mechanically ventilated) within 2 months before dosing
  • Past or intended use of over the counter (OTC) or prescription medication (including herbal medications or vitamin supplements, nutritional supplements, herb-containing drug preparations (including Chinese medicines) within 14 days (or 5 half-lives of the drug (whichever is longer) prior to dosing. Exceptions are oral /hormone replacement therapy for females and paracetamol/acetaminophen at doses of ≤2 g/day
  • Any vaccination during the 4 weeks before enrolment or planned during the clinical study
  • Use of any medications within 3 months that may interfere with absorption, distribution, metabolism or excretion of the study intervention, or any medication that may result in induction or inhibition of microsomal enzymes
  • Plasma donation within 14 days of the screening or any blood donation/blood loss >450 mL during the last 30 days before screening. Blood and/or plasma should not be donated until 30 days after last study intervention
  • Current enrolment or past participation within the last 3 months (or 5 half-lives, whichever is longer) before signing of consent in any other clinical study involving an study intervention or any other type of medical research
  • Presence of surface antigen (HBsAg) at screening
  • Positive antibody test result at screening. NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled if a confirmatory negative hepatitis C ribonucleic acid (RNA) test is obtained and sustained viral response can be documented
  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention. NOTE: Test is optional and participants with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing
  • Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Polymerase chain reaction (PCR) test result at screening or admission
  • Positive drugs of abuse/alcohol screen at screening and at admission
  • Positive (HIV) antibody test at screening
  • Consumption of other foods or beverages (red wine, Seville oranges, grapefruit or grapefruit juice (including pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices)) that may affect drug-metabolising enzymes or transporters from 7 days prior to dosing until discharge
  • History of drug or alcohol abuse or excessive intake of alcohol within the 12 months prior to first dosing, or evidence of such abuse as indicated by the laboratory assays conducted at screening or admission. Intake of alcohol above the official recommendation, defined as the regular consumption of more than 24 g of alcohol per day for men or 12 g of alcohol per day for women. Inability to abstain from alcohol for 24 hours before dosing until discharge
  • Inability to abstain from ingesting caffeine- or xanthine containing products (e.g. coffee, tea, cola drinks, energy drinks and chocolate) for 24 hours before dosing until discharge
  • History of illicit drug abuse within the last 12 months
  • Sensitivity to any components of the study intervention or other allergy that, in the opinion of the investigator, contraindicates participation in the study, including lactose intolerance
  • Inability to abstain from intensive muscular effort. Participants should not engage in any strenuous activity from 72 hours prior to admission to the CRU until after their discharge
  • Smoking or use of tobacco or nicotine-containing products (including nicotine patches) within 3 months prior to dosing, during the study until discharge. Status will be confirmed with a urine cotinine at screening and at admission
  • Had been on a diet incompatible with the on-study diet (i.e. unusual meal habits, special diet requirements or unwillingness to eat the food provided in the study, e.g. vegetarian nor vegan), in the opinion of the investigator or designee, within the 30 days prior to the first dosing and throughout the study
  • Venous status at forearm or dorsal hand making it difficult to insert a venous peripheral catheter
  • Vulnerable subjects, e.g. kept in detention, protected adults under guardianship, trusteeship or committed to an institution by governmental or juridical order
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort 1 : Healthy Japanese Participants

    Participants will receive Elafibranor 80 mg once daily on Day 1 to Day 18.

    Drug: Elafibranor

  • Experimental
    Cohort 2: Healthy Non-Asian Participants

    Participants will receive Elafibranor 80 mg once daily on Day 1 to Day 18.

    Drug: Elafibranor

Interventions

06

What researchers measure

Primary outcomes

  1. Noncompartmental Pharmacokinetics (PK) of Elafibranor and its Metabolite GFT1007: Area Under the Concentration-time Curve Over the Dosing Interval from Time 0 to 24 hours(AUCτ)

    AUCτ will be recorded from the PK blood samples collected.

    Time frame: Day 1 and Day 18

  2. Noncompartmental PK of Elafibranor and its Metabolite GFT1007: Maximum (peak) Observed Plasma Drug Concentration (Cmax)

    Cmax will be recorded from the PK blood samples collected.

    Time frame: Day 1 and Day 18

  3. Noncompartmental PK of Elafibranor and its Metabolite GFT1007: Time to Maximum Observed Drug Concentration (Tmax)

    Tmax will be recorded from the PK blood samples collected.

    Time frame: Day 1 and Day 18

  4. Noncompartmental PK of Elafibranor and its Metabolite GFT1007: Trough Observed Plasma Concentration Before Dosing or at the end of the Dosing Interval (Ctrough)

    Ctrough will be recorded from the PK blood samples collected.

    Time frame: Day 1 and Day 18

  5. Geometric Mean Ratios (GMR) of Elafibranor and and its Metabolite GFT1007: Area Under the Concentration-time Curve Over the Dosing Interval from Time 0 to 24 hours(AUCτ) at Steady State

    AUCτ at steady state will be recorded from the PK blood samples collected.

    Time frame: Day 18

  6. GMR of Elafibranor and and its Metabolite GFT1007: Maximum (peak) Observed Plasma Drug Concentration (Cmax) at Steady State

    Cmax at steady state will be recorded from the PK blood samples collected.

    Time frame: Day 18

Secondary outcomes

  1. Percentage of Participants With Clinically Significant changes in Laboratory Parameters (blood chemistry, hematology and coagulation)

    Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported. The clinical significance will be decided by the investigator.

    Time frame: Baseline up to Day 19

  2. Percentage of Participants With Clinically Significant Changes in Physical Examination

    Percentage of participants with clinically significant changes in physical examination findings will be reported. The clinical significance will be decided by the investigator.

    Time frame: Baseline up to Day 19

  3. Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Readings

    Percentage of participants with clinically significant changes in ECG readings will be reported. The clinical significance will be decided by the investigator.

    Time frame: Baseline up to Day 19

  4. Percentage of Participants With Clinically Significant Changes in Vital Signs

    Percentage of participants with clinically significant changes in Vital Signs will be reported. The clinical significance will be decided by the investigator.

    Time frame: Baseline up to Day 19

  5. Percentage of Participants With Treatment Emergent Adverse Event (TEAEs) and Adverse Events of Special Interest (AESIs)

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AESIs are AEs that may not be serious but are of special importance to a particular drug or class of drugs.

    Time frame: Baseline up to Day 19

07

Study locations

2 sites
  • Collaborative Neuroscience Research LLC
    Long Beach, California 90806, United States
  • Collaborative Neuroscience Research, LLC
    Los Alamitos, California 90720, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Mar 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Sep 16, 2022
StartActual
Sep 19, 2022
Primary completionActual
Mar 10, 2023
CompletionActual
Mar 10, 2023
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05543369
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Sep 16, 2022
Start date
Sep 19, 2022
Primary completion
Mar 10, 2023
Completion
Mar 10, 2023
Last update
Feb 20, 2025

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion